COVID-19 OTC Antigen Test

COVID-19 OTC Antigen Test

Regular price
$240.00
Sale price
$240.00

A COVID-19 Rapid Test for Home Use Without the Hassle of Labs!

 

The InteliSwab™ COVID-19 Rapid Test detects active infection from a self-collected sample using its built-in swab. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution, and the result appears on the test stick within 30 minutes. No instruments, batteries, smartphone or laboratory analysis needed! InteliSwab™ is one of only six rapid tests authorized for OTC use, and can be used for both symptomatic and asymptomatic use. 

  • Detects the Omicron & Delta variants
  • Approved for Over-The-Counter (OTC) Use 
  • Easy to Use
  • Accurate (test and retest! - 2x tests in each pack)
  • Quick & efficient at-home test
  • No lab tests/equipment needed
  • No hidden fees or costs
  • 84% sensitivity and 98% specificity

Available in packs of 6 or 24. Each pack (unit) contains two tests

Please note our current supply is short dated and expire at the end of Sep through the end of November 2022. These have received a shelf life extension as noted here, so these now expire from the end of Dec 2022 through Feb 2023

Questions? Need more information? Please contact us at 360-861-6199 or support@physician360.co 

Watch the Training Video below

All sales final, no refunds/returns for this product/service 

Authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwab® was previously authorized for use in adults and in children 15 to 17 when administered by an adult.

===========================================================

This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.


This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.


This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

 

x